Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

R. Fleischmann, Alan Friedman, Edit Drescher, Atul Singhal, Gregorio Cortes-Maisonet, Thao Doan, Wenjing Lü, Zailong Wang, Ahmed Nader, William Housley, Stanley Cohen, Peter C. Taylor, Ricardo Blanco